ClinicalTrials HQ

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Active, not recruiting · NCT05899673 · Registry updated 2025-10-14
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver DiseaseCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorderActive, not recruitingPhase 32025-10-14NCT05899673

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Takeda163

10 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Addenbrooke's HospitalCambridgeUnited Kingdom40
Hospital Nélio MendonçaFunchalPortugal2
Medical University of South Carolina - Hollings Cancer Center - PPDSCharlestonUnited States1
Medizinische Universitat Wien (Medical University of Vienna)ViennaAustria1
Royal Infirmary of Edinburgh - PPDSEdinburghUnited Kingdom2
Stanford Medicine Outpatient CenterRedwood CityUnited States4
UCSD Altman Clinical and Translational Research InstituteLa JollaUnited States2
UF Clinical and Translational Science InstituteGainesvilleUnited States1
University Of Iowa Hospitals And ClinicsIowa CityUnited States10
Universitätsklinikum der RWTH AachenAachenGermany1